Koenig Martial, Joyal France, Fritzler Marvin J, Roussin André, Abrahamowicz Michal, Boire Gilles, Goulet Jean-Richard, Rich Eric, Grodzicky Tamara, Raymond Yves, Senécal Jean-Luc
Notre-Dame Hospital, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Arthritis Rheum. 2008 Dec;58(12):3902-12. doi: 10.1002/art.24038.
To identify in patients with Raynaud's phenomenon (RP) independent markers that predict progression to definite systemic sclerosis (SSc) and to determine in patients with progression to SSc the type and sequence of microvascular damage and its relationship to SSc-specific autoantibodies.
Consecutive patients referred for evaluation of RP who had no definite connective tissue disease were evaluated for microvascular damage by nailfold capillary microscopy (NCM) and for anticentromere (anti-CENP-B), anti-Th/To, anti-topoisomerase I, and anti-RNA polymerase III (anti-RNAP III) autoantibodies by specific assays. Patients were studied prospectively.
Of the 586 patients who were followed up for 3,197 person-years, 74 (12.6%) developed definite SSc. A characteristic sequence of microvascular damage was identified, starting with enlarged capillaries, followed by capillary loss, and then by capillary telangiectases. Definite SSc was diagnosed in close temporal relationship to capillary loss. Enlarged capillaries, capillary loss, and SSc-specific autoantibodies independently predicted definite SSc. Anti-CENP-B and anti-Th/To antibodies predicted enlarged capillaries; these autoantibodies and anti-RNAP III predicted capillary loss. Each autoantibody was associated with a distinct time course of microvascular damage. At followup, 79.5% of patients with 1 of these autoantibodies and abnormal findings on NCM at baseline had developed definite SSc. Patients with both baseline predictors were 60 times more likely to develop definite SSc. The data validated the proposed criteria for early SSc.
In RP evolving to definite SSc, microvascular damage is dynamic and sequential, while SSc-specific autoantibodies are associated with the course and type of capillary abnormalities. Abnormal findings on NCM at baseline together with an SSc-specific autoantibody indicate a very high probability of developing definite SSc, whereas their absence rules out this outcome.
在雷诺现象(RP)患者中识别可预测进展为确诊系统性硬化症(SSc)的独立标志物,并在进展为SSc的患者中确定微血管损伤的类型和顺序及其与SSc特异性自身抗体的关系。
对因RP转诊评估且无确诊结缔组织病的连续患者,通过甲襞毛细血管显微镜检查(NCM)评估微血管损伤,并通过特异性检测评估抗着丝点(抗CENP-B)、抗Th/To、抗拓扑异构酶I和抗RNA聚合酶III(抗RNAP III)自身抗体。对患者进行前瞻性研究。
在586例随访3197人年的患者中,74例(12.6%)发展为确诊SSc。确定了微血管损伤的特征性顺序,始于毛细血管扩张,接着是毛细血管缺失,然后是毛细血管扩张。确诊SSc与毛细血管缺失在时间上密切相关。毛细血管扩张、毛细血管缺失和SSc特异性自身抗体可独立预测确诊SSc。抗CENP-B和抗Th/To抗体预测毛细血管扩张;这些自身抗体和抗RNAP III预测毛细血管缺失。每种自身抗体都与微血管损伤的不同时间进程相关。随访时,基线时具有这些自身抗体之一且NCM检查结果异常的患者中,79.5%发展为确诊SSc。同时具有两种基线预测指标的患者发展为确诊SSc的可能性高60倍。数据验证了所提出的早期SSc标准。
在进展为确诊SSc的RP中,微血管损伤是动态且有顺序的,而SSc特异性自身抗体与毛细血管异常的进程和类型相关。基线时NCM检查结果异常以及存在SSc特异性自身抗体表明发展为确诊SSc的可能性非常高,而两者均无则可排除这种结果。